



## ASX ANNOUNCEMENT

### Federal R&D Tax Credit Received

---

**Sydney Australia, 24 March 2017:** Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received a \$5,590,235 cash refund under the Federal Government's R&D Tax Incentive Scheme.

The refund relates to the costs of research and development which qualify as eligible R&D expenditure under the Federal Government's Scheme. The funds will be used to advance Benitec's human therapeutic programs in gene silencing.

For further information regarding Benitec please contact the persons below or visit the Benitec website at [www.benitec.com](http://www.benitec.com).

#### ***Australia Investor Relations***

Market Eye  
Orla Keegan  
Director  
Tel: +61 (2) 8097 1201  
Email: [orla.keegan@marketeye.com.au](mailto:orla.keegan@marketeye.com.au)

#### ***United States Investor Relations***

M Group Strategic Communications  
Jay Morakis  
Managing Director  
Tel: +1 212.266.0190  
Email: [jmorakis@MGroupSC.com](mailto:jmorakis@MGroupSC.com)

#### ***About Benitec Biopharma Limited:***

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.

#### ***Safe Harbor Statement:***

This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in the press release are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialize its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.